17:58 , Jul 20, 2018 |  BC Week In Review  |  Company News

Kite looks to Gadeta for gamma delta T cell tech

Kite Pharma Inc. and Gadeta B.V. (Utrecht, the Netherlands) partnered to develop T cell therapies that express gamma delta TCRs for hematologic malignancies and solid tumors using Gadeta's platform. Kite, a subsidiary of Gilead Sciences...
20:06 , Jul 19, 2018 |  BC Extra  |  Company News

Kite, Gadeta in gamma delta T cell deal

Kite Pharma Inc. and Gadeta B.V. (Utrecht, the Netherlands) partnered to develop T cell therapies that express gamma delta TCRs for hematologic malignancies and solid tumors using Gadeta's platform. Kite, a subsidiary of Gilead Sciences...
01:19 , Jan 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Age-related macular degeneration (AMD) Patient sample, cell culture and mouse studies suggest inhibiting cGAS, CASP4, GSDMD, IFNB1, IFNAR1, IRF3 or STAT2 could help treat geographic atrophy. In tissue samples from patients, levels of cGAS,...
19:07 , Dec 8, 2017 |  BC Week In Review  |  Company News

bluebird, TC BioPharm in gamma delta CAR T deal

bluebird bio Inc. (NASDAQ:BLUE) and TC BioPharm Ltd. (Edinburgh, U.K.) partnered on Dec. 7 to discover and develop gamma delta chimeric antigen receptor (CAR) T cells to treat hematologic malignancies and solid tumors using TC...
23:58 , Dec 7, 2017 |  BC Extra  |  Company News

bluebird, TC BioPharm in gamma delta CAR T deal

bluebird bio Inc. (NASDAQ:BLUE) and TC BioPharm Ltd. (Edinburgh, U.K.) partnered to discover and develop gamma delta chimeric antigen receptor (CAR) T cells to treat hematologic malignancies and solid tumors using TC BioPharm's ImmuniCAR technology....
20:05 , Nov 6, 2017 |  BC Extra  |  Preclinical News

Team identifies new targets to treat myocardial infarction

In a paper published Monday in...
21:18 , Jul 3, 2017 |  BC Extra  |  Preclinical News

Researchers identify new TB inhibitors

In two separate papers published in...
22:16 , Jun 1, 2017 |  BC Innovations  |  Translation in Brief

Odd couples

A Stanford University team has built synthetic ligands that force cytokine receptor subunits into unnatural pairings, and showed the "synthekines" were able to trigger new patterns of signaling and cytokine secretion in blood cells. The...
20:27 , May 9, 2017 |  BC Extra  |  Company News

Takeda gets option to buy T cell play GammaDelta

T cell therapy developer GammaDelta Therapeutics Ltd. (London, U.K.) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) an exclusive option to acquire the company as part of a discovery and development agreement targeting autoimmune and inflammatory diseases...
21:37 , May 5, 2017 |  BioCentury  |  Finance

LSP checks in

ImCheck Therapeutics S.A.S. ’s focus on checkpoint receptors that are expressed on a subset of T cells that are different from the cellular targets of other checkpoint modulators convinced LSP to make its first immuno-oncology...